Renaissance Technologies’s Gyre Therapeutics GYRE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-13,900
| Closed | -$166K | – | 3666 |
|
|
2024
Q2 | $166K | Buy |
+13,900
| New | +$191K | ﹤0.01% | 3086 |
|
|
2024
Q1 | – | Sell |
-17,085
| Closed | -$439K | – | 3855 |
|
|
2023
Q4 | $439K | Sell |
17,085
-22,294
| -57% | -$316K | ﹤0.01% | 2840 |
|
|
2023
Q3 | $285K | Sell |
39,379
-12,247
| -24% | -$82K | ﹤0.01% | 2948 |
|
|
2023
Q2 | $272K | Sell |
51,626
-6,766
| -12% | -$24.3K | ﹤0.01% | 3169 |
|
|
2023
Q1 | $181K | Sell |
58,392
-99,873
| -63% | -$380K | ﹤0.01% | 3318 |
|
|
2022
Q4 | $626K | Buy |
158,265
+11,429
| +8% | +$46.6K | ﹤0.01% | 2812 |
|
|
2022
Q3 | $555K | Buy |
146,836
+40,571
| +38% | +$515K | ﹤0.01% | 2873 |
|
|
2022
Q2 | $1.42M | Sell |
106,265
-49,717
| -32% | -$330K | ﹤0.01% | 2459 |
|
|
2022
Q1 | $772K | Sell |
155,982
-80,272
| -34% | -$398K | ﹤0.01% | 2895 |
|
|
2021
Q4 | $1.62M | Buy |
236,254
+230,949
| +4,353% | +$3.95M | ﹤0.01% | 2306 |
|
|
2021
Q3 | $164K | Sell |
5,305
-54,455
| -91% | -$1.79M | ﹤0.01% | 3245 |
|
|
2021
Q2 | $1.94M | Buy |
+59,760
| New | +$2.05M | ﹤0.01% | 2280 |
|
|
2021
Q1 | – | Sell |
-19,401
| Closed | -$918K | – | 3464 |
|
|
2020
Q4 | $918K | Sell |
19,401
-14,066
| -42% | -$609K | ﹤0.01% | 2543 |
|
|
2020
Q3 | $1.08M | Buy |
33,467
+22,426
| +203% | +$878K | ﹤0.01% | 2477 |
|
|
2020
Q2 | $486K | Buy |
11,041
+5,267
| +91% | +$247K | ﹤0.01% | 2893 |
|
|
2020
Q1 | $189K | Sell |
5,774
-774
| -12% | -$35.6K | ﹤0.01% | 3114 |
|
|
2019
Q4 | $334K | Buy |
+6,548
| New | +$274K | ﹤0.01% | 3044 |
|
|
2019
Q3 | – | Sell |
-2,134
| Closed | -$118K | – | 3525 |
|
|
2019
Q2 | $118K | Sell |
2,134
-21,425
| -91% | -$1.34M | ﹤0.01% | 3376 |
|
|
2019
Q1 | $1.43M | Sell |
23,559
-2,974
| -11% | -$191K | ﹤0.01% | 2495 |
|
|
2018
Q4 | $1.57M | Sell |
26,533
-32,263
| -55% | -$2.38M | ﹤0.01% | 2355 |
|
|
2018
Q3 | $4.75M | Sell |
58,796
-19,414
| -25% | -$1.54M | ﹤0.01% | 1832 |
|
|
2018
Q2 | $6.84M | Buy |
78,210
+4,027
| +5% | +$706K | 0.01% | 1577 |
|
|
2018
Q1 | $14.4M | Buy |
74,183
+26,800
| +57% | +$5M | 0.02% | 1136 |
|
|
2017
Q4 | $4.85M | Buy |
47,383
+2,880
| +6% | +$147K | 0.01% | 1831 |
|
|
2017
Q3 | $1.69M | Sell |
44,503
-787
| -2% | -$23.6K | ﹤0.01% | 2363 |
|
|
2017
Q2 | $1.58M | Buy |
45,290
+36,520
| +416% | +$1.31M | ﹤0.01% | 2385 |
|
|
2017
Q1 | $620K | Buy |
8,770
+5,344
| +156% | +$312K | ﹤0.01% | 2704 |
|
|
2016
Q4 | $251K | Buy |
3,426
+1,760
| +106% | +$158K | ﹤0.01% | 2944 |
|
|
2016
Q3 | $227K | Buy |
1,666
+754
| +83% | +$114K | ﹤0.01% | 3034 |
|
|
2016
Q2 | $156K | Buy |
912
+320
| +54% | +$54.6K | ﹤0.01% | 3095 |
|
|
2016
Q1 | $112K | Sell |
592
-90
| -13% | -$21.7K | ﹤0.01% | 3195 |
|
|
2015
Q4 | $240K | Buy |
682
+127
| +23% | +$50K | ﹤0.01% | 2946 |
|
|
2015
Q3 | $291K | Buy |
555
+132
| +31% | +$201K | ﹤0.01% | 2773 |
|
|
2015
Q2 | $928K | Buy |
423
+98
| +30% | +$196K | ﹤0.01% | 2484 |
|
|
2015
Q1 | $761K | Buy |
325
+120
| +59% | +$248K | ﹤0.01% | 2439 |
|
|
2014
Q4 | $425K | Buy |
205
+161
| +366% | +$310K | ﹤0.01% | 2482 |
|
|
2014
Q3 | $88K | Buy |
44
+6
| +16% | +$14.8K | ﹤0.01% | 2677 |
|
|
2014
Q2 | $134K | Buy |
+38
| New | +$124K | ﹤0.01% | 2628 |
|
|
2014
Q1 | – | Sell |
-182
| Closed | -$594K | – | 2906 |
|
|
2013
Q4 | $594K | Sell |
182
-217
| -54% | -$855K | ﹤0.01% | 2298 |
|
|
2013
Q3 | $1.67M | Buy |
399
+60
| +18% | +$241K | ﹤0.01% | 1764 |
|
|
2013
Q2 | $1.14M | Buy |
+339
| New | +$1.29M | ﹤0.01% | 1874 |
|
Other funds holding GYRE
AACP
Renaissance Technologies's GYRE Position: Q3 2024 in Review
Renaissance Technologies sold out of Gyre Therapeutics (GYRE) in Q3 2024, closing a stake of 13,900 shares — an estimated $166K sold.
Renaissance Technologies first reported a position in GYRE in Q2 2013 and held it in 41 quarters. The position peaked at $14.4M in Q1 2018. 37 funds tracked by Wall St. Rank hold GYRE as of Q3 2024.
- Renaissance Technologies reported no remaining Gyre Therapeutics position as of Q3 2024 after selling out during the quarter.
- Renaissance Technologies sold 13,900 Gyre Therapeutics shares in Q3 2024, an estimated $166K.
- Renaissance Technologies first reported a position in Gyre Therapeutics in Q2 2013 and held it in 41 quarters.
- Renaissance Technologies's Gyre Therapeutics position peaked at $14.4M in Q1 2018.
- 37 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q3 2024.
Based on Renaissance Technologies's 13F filing for Q3 2024, filed 13 Nov 2024.